I guess Zacks did too;
"Zacks Investment Research is reiterating its 'Buy' recommendation on shares of Trius following the solid top-line data from ESTABLISH-2. We see a partnership for the European commercialization of tedizolid as the single biggest catalyst for the shares in 2013. We believe the stock is well-positioned, with over $80 million in cash and investments, to continue its solid run into the presentation of the full data in September 2013 and the U.S. NDA filing in October 2013. Our price target is $12 per share"